Indication
Thrombocytopenia associated with chronic hepatitis C
Thrombocytopenia associated with chronic hepatitis C is a hematologic complication characterized by abnormally low circulating platelet counts, typically below 150,000 per microliter, in patients with persistent hepatitis C virus (HCV) infection. Read more about Thrombocytopenia associated with chronic hepatitis C
16 drugs 14 manufacturers
Drugs that treat it
Common Thrombocytopenia associated with chronic hepatitis C therapies.
PROMACTA (eltrombopag olamine)
PROMACTA (eltrombopag olamine)
ALVAIZ (eltrombopag choline)
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThrombocytopenia associated with chronic hepatitis C is a hematologic complication characterized by abnormally low circulating platelet counts, typically below 150,000 per microliter, in patients with persistent hepatitis C virus (HCV) infection.
Its pathogenesis is multifactorial, stemming from impaired hepatic synthesis of thrombopoietin, splenic platelet sequestration secondary to portal hypertension, direct viral suppression of bone marrow megakaryopoiesis, and immune-mediated platelet destruction.
While this condition heightens bleeding risks during invasive procedures, it historically represented a major clinical barrier by precluding the initiation or dose maintenance of interferon-based antiviral regimens.
- brieflands.com
Thrombocytopenia associated with chronic hepatitis C is a hematologic complication characterized by abnormally low circulating platelet counts, typically below 150,000 per microliter, in patients with persistent hepatitis C virus (HCV) infection
- nih.gov
Its pathogenesis is multifactorial, stemming from impaired hepatic synthesis of thrombopoietin, splenic platelet sequestration secondary to portal hypertension, direct viral suppression of bone marrow megakaryopoiesis, and immune-mediated platelet destruction While this condition heightens bleeding risks during invasive procedures, it historically represented a major clinical barrier by precluding the initiation or dose maintenance of interferon-based antiviral regimens
- unair.ac.id
Its pathogenesis is multifactorial, stemming from impaired hepatic synthesis of thrombopoietin, splenic platelet sequestration secondary to portal hypertension, direct viral suppression of bone marrow megakaryopoiesis, and immune-mediated platelet destruction
- ashpublications.org
Its pathogenesis is multifactorial, stemming from impaired hepatic synthesis of thrombopoietin, splenic platelet sequestration secondary to portal hypertension, direct viral suppression of bone marrow megakaryopoiesis, and immune-mediated platelet destruction
- fiercepharma.com
While this condition heightens bleeding risks during invasive procedures, it historically represented a major clinical barrier by precluding the initiation or dose maintenance of interferon-based antiviral regimens
Personalize your experience
Follow Thrombocytopenia associated with chronic hepatitis C and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.